AstraZeneca chief Pascal Soriot has got his Pfizer retaliation in first
AstraZeneca may be morphing into a company that concentrates on its strengths, but its profits profile needs attention
AstraZeneca chief executive Pascal Soriot started with the standard disclaimer that he couldn’t possibly comment on any past or future takeover approach from Pfizer or anyone else. Fair enough. Then, without joining any dots, he offered a series of reasons why his shareholders would be crazy to sell their firm at this time for a conventional takeover premium of 20% or so.
Takeovers in general? "Sometimes they can work, but often they are very disruptive," he said. How about an invigorating Glaxo/Novartis-style asset trade? He sounded keen. His rivals had found a "win-win" deal and he might have something up his own sleeve for AstraZeneca’s small neuroscience and infection divisions. "We are exploring a variety of options" and "we can’t do everything ourselves".
More From Around the Web
Check out these Articles
- AstraZeneca to reveal diabetes trial results in US this week
- Legal Briefs: JK on the 120 Days
- We shouldn’t push dubious ‘pink Viagra’ pills on women an...
- G&L Scientific Inc. Announces Opening of New Offices in Cambridge, Mass...
- Global Life Sciences BPO Market Analysis: CRO, CMO Services and Forecast to...
- A Lay Person’s Guide to the Hobby Lobby Decision
- Top Algae DHA Innovator Sells 100% Algae Oil to Pharmas at Lower Price, Hig...
- Pfizer-AstraZeneca: MPs grill pharma chiefs on takeover – live
- 2015-2016 Report of the Committee on Law Enforcement/Legislation